Despite its potential as a therapeutic target, targeting STAT5 comes with challenges. Firstly, the structural similarity between STAT5 and other STAT proteins makes it difficult to develop specific inhibitors without affecting other pathways. Additionally, the development of resistance to STAT5 inhibitors is a significant concern. Cancer cells can activate alternative pathways to maintain survival in the presence of STAT5 inhibition. Therefore, combination therapies that target multiple signaling pathways may be necessary to overcome resistance.
